RadarScope: ABBV — Analiza Fundamentala

Market Cap

$469.9B

P/E Ratio

74.9

Profit Margin

9.8%

ROE

-136.5%

📈 Earnings Report — 2026-07

Ultimul trimestru raportat

EPS Actual

$3.65

▲ 37.7% QoQ▲ 22.9% YoY

EPS Estimat

$3.61

Beat by 1.1%

Revenue Actual

$16.99B

▲ 13.3% QoQ▲ 10.2% YoY

Revenue Estimat

$16.80B

Beat by 1.1%

Istoric Ultimele 4 Trimestre

2026-07

EPS Actual

$3.65

EPS Est.

$3.61

Revenue

$16.99B

Beat/Miss

Beat by 1.1%

2026-04

EPS Actual

$2.65

EPS Est.

$2.59

Revenue

$15.00B

Beat/Miss

Beat by 2.3%

2026-02

EPS Actual

$2.71

EPS Est.

$2.65

Revenue

$16.62B

Beat/Miss

Beat by 2.3%

2025-10

EPS Actual

$1.86

EPS Est.

$1.77

Revenue

$15.78B

Beat/Miss

Beat by 5.1%

Urmatorul Raport

Data

2026-10-30

EPS Estimat

$3.86

Revenue Estimat

$17.31B

💰 Dividende Recente

2026-07

$1.73

Yield: 2.80%

Plata: 2026-08

2026-04

$1.73

Yield: 3.23%

Plata: 2026-05

2026-01

$1.73

Yield: 3.10%

Plata: 2026-02

2025-10

$1.64

Yield: 2.90%

Plata: 2025-11

📊 Scoruri Companie

Crestere 7/10

Revenue & Profit Growth

Evaluare 3/10

P/E · P/B · P/S

Calitate 7/10

Marje · ROE · Datorii

Risc 3/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.

💡 Disponibil pe Trader / Elite

🐂 BULL CASE

Disponibil pe Trader / Elite

🐻 BEAR CASE

Disponibil pe Trader / Elite

TINE Upgrade la Trader sau Elite pentru verdictul AI.

📖 Indicatorii lui Lynch — concluzii rapide dupa Peter Lynch

PEG — P/E in contextul cresterii

N/A

PEG indisponibil (profit in scadere). PEG-ul Lynch nu se aplica firmelor fara profit sau cu profit in scadere.

P/E vs istoria proprie si sectorul

P/E acum 74.9.
vs media proprie 5 ani (54.5): PESTE media sa
vs sector Healthcare (22.7): PESTE sector
Lynch: compara P/E cu propria istorie si media industriei, nu in absolut.

Procentul din vanzari (concentrare produs)

DIVERSIFICAT

SKYRIZI 30% · RINVOQ 14% · H U M I R A 8% · Botox Therapeutic 6%
Lynch: un produs genial care aduce sub ~10% din venituri nu misca actiunea.

Cash si datorie

DATORIE NETA

Datorie neta pe actiune $35.71 (mai multa datorie decat cash).
Datorie/Capital -11.93 DATORIE MICA — decide supravietuirea in vremuri grele (esential la ciclice si turnarounds).
Tip datorie: OK — TERMEN LUNG — majoritar pe termen lung (obligatiuni = timp de manevra). Scurt $8.7B / Lung $59.6B.

Marje de profit

MARJE MEDII

Bruta 71.5% · Operationala 29.3% · Neta 9.8%. Marje decente.

Inventare vs vanzari

ATENTIE

Stocurile cresc mai repede ca vanzarile (inventar +18% vs vanzari +9%) — semnal de alarma clasic.

Povestea in 2 minute

De ce o detii: Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.
Ce trebuie sa mearga bine: Disponibil pe Trader / Elite
Obstacole: Disponibil pe Trader / Elite
Lynch: daca nu poti explica coerent in 2 minute de ce o detii, nu o intelegi.

🔬 Analiza Fundamentala Avansata · an fiscal 2025-12-31

🏦 Altman Z-Score

2.46 ZONA GRI

X1 Capital de lucru / Active	-0.106	x1.2
X2 Profit reportat / Active	-0.116	x1.4
X3 EBIT / Active	0.071	x3.3
X4 Capitalizare / Datorii	3.426	x0.6
X5 Vanzari / Active	0.457	x1.0

Praguri Altman (1968): >2,99 sigur · 1,81–2,99 gri · <1,81 pericol de faliment

💪 Piotroski F-Score

7/9 ACCEPTABIL

✓ROA pozitiv3.15%

✓Cash flow operational pozitiv19.03B

✗ROA in crestere3.15% vs 3.17%

✓Cash flow > Profit net (calitate)19.03B vs 4.23B

✓Datorie pe termen lung in scadere44.0% vs 44.6% din active

✓Lichiditate curenta in crestere0.67 vs 0.66

✗Fara emisiune de actiuni noi1767.9M vs 1765.3M

✓Marja bruta in crestere70.2% vs 70.0%

✓Rotatia activelor in crestere0.46 vs 0.42

9 teste binare (Piotroski, 2000). 8–9 = putere financiara · 0–2 = slabiciune

⚖️ ROIC vs WACC

+4.96pp CREEAZA VALOARE

ROIC (randamentul capitalului)	10.32%
WACC (costul capitalului)	5.36%

Ipoteze (la vedere):
Rata fara risc 4.2% (USD) · Beta 0.28 · Prima de risc 5.5%
Cost capitaluri proprii 5.74% · Cost datorie 4.29% · Impozit efectiv 35.8%

Metode publice: Altman, E. (1968), Journal of Finance · Piotroski, J. (2000), Journal of Accounting Research · ROIC/WACC prin CAPM. Fiecare cifra isi arata componentele si pragurile — poti reface calculul manual.

📊 Metrici Fundamentale

P/E TTM74.9

P/B TTM-79.37

P/S TTM7.30

EV/EBITDA25.2

Gross Margin71.5%

Operating Margin29.3%

Net Margin9.8%

ROE-136.5%

ROA4.7%

Debt/Equity-11.93

Current Ratio0.81

FCF Yield4.2%

Dividend Yield2.57%

Beta0.28

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2026-06	$17.0B	$12.7B	$3.6B	$2.04
2026-03	$15.0B	$10.8B	$699.0M	$0.39
2025-12	$16.6B	$12.1B	$1.8B	$1.02
2025-09	$15.8B	$10.5B	$186.0M	$0.10

🏢 Profil Companie

CEORobert A. Michael

Angajati57000

IPO2013-01-02

Websitehttps://www.abbvie.com...

52W High$267.47

52W Low$190.75

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthriti...

🎯 Score Breakdown

Calitate Companie (Q) 7/10

Risc Speculativ (R) 3/10

Scor AI RadarScope 0/100

VERDICT FINAL

TINE

Upgrade la Trader sau Elite pentru verdictul AI.

🔒 Analiza completa disponibila cu cont SignalRadar